Synapse - Heiko Schoder

Results (153)

The impact of semiautomatic segmentation methods on metabolic tumor volume, intensity, and dissemination radiomics in (18)F-FDG PET scans of patients with classical Hodgkin lymphoma

Journal Article

Driessen, J.; Zwezerijnen, G. J. C.; Schöder, H.; Drees, E. E. E.; Kersten, M. J.; Moskowitz, A. J.; Moskowitz, C. H.; Eertink, J. J.; de Vet, H. C. W.; Hoekstra, O. S.; more...
Journal of Nuclear Medicine (2022)

Fulltext@MSK | Save

Patterns of relapse and risk reduction following tumor debulking by bridging radiotherapy prior to chimeric antigen receptor T cell therapy in non-Hodgkin lymphoma

Meeting Abstract

Hubbeling, H. G.; Silverman, E. A.; Michaud, L.; Flynn, J.; Devlin, S.; Wijetunga, N. A.; Alarcon Tomas, A.; Shouval, R.; Palomba, M. L.; Batlevi, C. L.; more...
International Journal of Radiation Oncology, Biology, Physics (2022)

Fulltext@MSK | Save

Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma

Journal Article

Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
Blood Cancer Journal (2022)

Fulltext@MSK | Save

Phase I/Ib study of the efficacy and safety of buparlisib and ibrutinib therapy in MCL, FL, and DLBCL with serial cell-free DNA monitoring

Journal Article

Stewart, C. M.; Michaud, L.; Whiting, K.; Nakajima, R.; Nichols, C.; De Frank, S.; Hamlin, P. A. Jr; Matasar, M. J.; Gerecitano, J. F.; Drullinsky, P.; more...
Clinical Cancer Research (2022)

Fulltext@MSK | Save

Quantitative change in metabolic tumor volume may assist in distinguishing between pseudoprogressors and responders in patients with relapsed/refractory classical Hodgkin lymphoma treated with PD-1 blockade

Meeting Abstract

Wills, B.; Michaud, L.; Schöder, H.; Ganesan, N.; Moskowitz, C. H.; Straus, D. J.; Falchi, L.; Matasar, M. J.; Zelenetz, A. D.; Joffe, E.; more...
Blood (2021)

Fulltext@MSK | Save

Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)

Meeting Abstract

Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
Blood (2021)

Fulltext@MSK | Save

Favorable outcomes of patients with limited-stage ocular adnexal DLBCL treated in the rituximab era: Long-term follow-up of a single center experience

Meeting Abstract

Qualls, D.; Batlevi, C. L.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; Kumar, A.; Matasar, M. J.; more...
Blood (2021)

Fulltext@MSK | Save

Effect of brentuximab vedotin addition to chemotherapy and prognostic factors in patients with relapsed/refractory hodgkin lymphoma: A large multi-trial analysis based on individual patient data

Meeting Abstract

Driessen, J.; de Wit, F.; Herrera, A. F.; Zinzani, P. L. L.; LaCasce, A. S.; Moskowitz, C. H.; Garcia-Sanz, R.; Cole, P. D.; Fuchs, M.; Mueller, H.; more...
Blood (2021)

Fulltext@MSK | Save

A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas

Journal Article

Moskowitz, A. J.; Ghione, P.; Jacobsen, E.; Ruan, J.; Schatz, J. H.; Noor, S.; Myskowski, P.; Vardhana, S.; Ganesan, N.; Hancock, H.; more...
Blood (2021)

Fulltext@MSK | Save

Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma

Journal Article

Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save